Ients treated with imatinib (recommended dose 800 mg/d). A small subset of DFSP lacking the classic t (17, 22) gene aberration seems to have no response to imatinib. Thus, cytogenetic studies that confirm PDGFB gene rearrangement may be necessary in predicting future clinical response, prior to imatinib therapy administration [5,11,15,16].Consent Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.Competing interests The authors declare that they have no competing interests. Authors’ contributions DMD was responsible for original conception and design, editing, English editing, search of the literature, correction, editorship of the manuscript. LAKK was responsible for acquisition, analysis and interpretation of data, English editing and search of the literature. IKA was responsible for the histology consulting and pathology examination. APT was responsible for correction, editing, revision, and approval of the final version. Author Details Luke’s Hospital, Department of General Surgery, Breast Division, Panorama, 55 236, Thessaloniki, Greece and 2Hippokrateio Hospital, Department of Cellular Pathology, Procyanidin B1MedChemExpress Procyanidin B1 Konstantinoupoleos 49, 546 42, Thessaloniki, Greece Received: 6 February 2010 Accepted: 3 June 2010 Published: 3 June?2010 Dragoumis et from: http://www.wjso.com/content/8/1/48 This article is availableal; licensee BioMed8:48 the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. World Journal ofAccess article distributed under Ltd. is an Open Surgical Oncology 2010, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25447644 Central1StReferences 1. Lemm D, M ge LO, Mentzel T, H fken K: Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009, 135:653-65. 2. Bulliard C, Murali R, Chang LY, Brennan ME, French J: Subcutaneous dermatofibrosarcoma protuberans in skin of the breast: may mimic a primary breast lesion. Pathology 2007, 39:446-8. 3. Swan MC, Banwell PE, Hollowood K, Goodacre TE: Late recurrence of dermatofibrosarcoma protuberans in the female breast: a case report. Br J Plast Surg 2005, 58:84-7. 4. Cavusolu T, Yavuzer R, Tuncer S: Dermatofibrosarcoma protuberans of ?the breast. Aesthetic Plast Surg 2003, 27:104-6. 5. DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK: Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004, 100:1008-16. 6. Ramakrishnan V, Shoher A, Ehrlich M, Powell S, Lucci A Jr: Atypical dermatofibrosarcoma protuberans in the breast. Breast J 2005, 11:217-8.Dragoumis et al. World Journal of Surgical Oncology 2010, 8:48 http://www.wjso.com/content/8/1/Page 5 of7.8.9.10.11. 12.13.14.15. 16.Goldblum JR, Tuthill RJ: CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol 1997, 19:147-53. Kim HJ, Lee JY, Kim SH, Seo YJ, Lee JH, Park JK, Kim MH, Cinn YW, Cho KH, Yoon TY: Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol 2007, 157:319-24. Kahn HJ, Fekete E, From L: Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIII.